Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tübingen
Clinical trial register · Germany

Clinical Trials in Tübingen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5081 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
5081
Studies in scope
all four open statuses
2880
Recruiting now
open to new participants
985
Lead sponsors
across recruiting studies
Top sites
Berlin 1591 Hamburg 896 Essen 767 Dresden 717 Heidelberg 626
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital Tuebingen78 Merck Sharp & Dohme LLC20 Hoffmann-La Roche12 Novartis Pharmaceuticals11 AbbVie11 Janssen Research & Development, LLC10 AstraZeneca9 Boehringer Ingelheim8 Sanofi7 Eli Lilly and Company7 Pfizer7 Philogen S.p.A.6 Takeda5 GlaxoSmithKline5 Bristol-Myers Squibb5 Women's Cancer Study Group GmbH5 Washington University School of Medicine5 Jena University Hospital4 Jaeb Center for Health Research4 German Cancer Research Center4 Regeneron Pharmaceuticals4 Exelixis4 Bayer4 AO Innovation Translation Center3 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest3 Show all 197
Site location
Berlin1591 Hamburg896 Essen767 Dresden717 Heidelberg626 Cologne619 Leipzig515 München513 Hanover488 Tübingen457 Bonn424 Düsseldorf409 Munich398 Freiburg im Breisgau392 Erlangen373 Frankfurt369 Münster359 Frankfurt am Main346 Ulm343 Mainz336 Würzburg299 Aachen267 Augsburg248 Kiel236 Lübeck225 Show all 642
All 642 locations
Target enrolment
to

Trials with a site in Tübingen

457 of 5081 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Berlin, Cologne, Erlangen, Leipzig, München, Tübingen, Würzburg
2027-02-03
Not yet open
Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congenital Heart Disease Undergoing Surgical Repair
NCT07486167Congenital Heart Disease, Cardiopulmonary Bypass, Mechanical Ventilation, Peep Titration in Lung Protective Ventilation
Charite University, Berlin, Germany
Phase 1/2
80
Tübingen
2027-01-01
Not yet open
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
NCT07932262Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV), Rheumatoid Arthritis (RA), IIM
University Hospital Tuebingen
Phase 1/2
36
Tübingen
2027-01
Not yet open
AbbVie
Phase 3
520
Freiburg im Breisgau, Karlsruhe, Tübingen, Ulm, Würzburg, Hanover, Bonn, Cologne
2026-11-30
Recruiting
Boehringer Ingelheim
Phase 1/2
55
Dresden, Essen, Tübingen
2026-10-01
Not yet open
Boston Scientific Corporation
Not applicable
30
Tübingen
2026-10-01
Recruiting
University Hospital Tuebingen
Phase 2
120
Dresden, Tübingen
2026-10
Recruiting
Philogen S.p.A.
Phase 2
180
Augsburg, Berlin, Essen, Halle, Kiel, Tübingen
2026-09-28
Recruiting
Evaluation of Low-thermal Argon Plasma Devitalization for the Treatment of CIN 2 Versus Standard of Active Surveillance
NCT07730645Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Intraepithelial Neoplasia Grade 2, CIN2
University Hospital Tuebingen
Not applicable
264
Tübingen
2026-09-24
Recruiting
University Hospital Tuebingen
Phase 2
84
Heidelberg, Tübingen, Berlin, Essen
2026-09-24
Recruiting
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870Locally Advanced Basal Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Augsburg, Berlin, Essen, Halle, Heidelberg, Kiel, Tübingen
2026-09
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Augsburg, Berlin, Essen, Halle, Heidelberg, Kiel, Tübingen
2026-09
Not yet open
University Hospital Tuebingen
Not applicable
54
Tübingen
2026-08-24
Recruiting
Hannover Medical School
Phase 3
150
Heidelberg, Tübingen, Regensburg, Würzburg, Hamburg, Hanover, Rostock, Aachen
2026-08-19
Recruiting
NG004 in Incomplete Spinal Cord Injury Patients
NCT07840196Acute Spinal Cord Injury (SCI), Spinal Cord Diseases, Spinal Cord Injuries, Trauma Nervous System
DrugNG004
NovaGo Therapeutics AG
Phase 1
120
Bayreuth, Bochum, Halle, Hamburg, Heidelberg, Murnau am Staffelsee, Tübingen
2026-08-05
Recruiting
Novartis Pharmaceuticals
Phase 2
100
Hamburg, Tübingen
2026-07-30
Recruiting
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
NCT07640542Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
MODAG GmbH
Early Phase 1
9
Tübingen
2026-07-29
Recruiting
OncoZenge AB
Phase 3
150
Cologne, Frankfurt am Main, Freiburg im Breisgau, Kiel, Tübingen
2026-07-07
Recruiting
Mitra Bio
Observational
2,000
Tübingen
2026-06-10
Recruiting
AstraZeneca
Phase 1/2
152
Essen, Jena, Rostock, Tübingen
2026-06-03
Recruiting
Bayer
Phase 3
117
Tübingen, Giessen, Cologne
2026-06-01
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Freiburg im Breisgau, Hamburg, Tübingen
2026-05-31
Recruiting
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
NCT07387198Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
135
Heidelberg, Mannheim, Tübingen, Regensburg, Würzburg, Hamburg, Frankfurt am Main, Bielefeld
2026-05-29
Recruiting
Pfizer
Phase 2
24
Münster, Leipzig, Tübingen, Wuppertal
2026-05-28
Recruiting
Takeda
Phase 2
222
Heidelberg, Tübingen, Potsdam, Frankfurt am Main, Göttingen, Dresden, Berlin
2026-05-17
Recruiting
ARTEMIS - The ARTEMIS Cohort
NCT07421219Non-progressive Congenital Ataxia, Ataxic Cerebral Palsy
Vastra Gotaland Region
Observational
50
Tübingen
2026-05-15
Recruiting
Ipsen
Phase 3
350
Berlin, Dresden, Hanover, Heidelberg, Leipzig, Magdeburg, Mainz, Tübingen
2026-05-14
Recruiting
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
NCT07531927Geographic Atrophy Secondary to Age-related Macular Degeneration
Okuvision GmbH
Not applicable
70
Hamburg, München, Stuttgart, Tübingen, Ulm
2026-05-05
Recruiting
Dr. Gerhard Mann chem.-pharm. Fabrik GmbH
Not applicable
160
Freiburg im Breisgau, Heidelberg, Tübingen, Munich, Nuremberg, Prien am Chiemsee, Ahaus, Brühl
2026-04-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
Tübingen
2026-04-30
Recruiting
Women's Cancer Study Group GmbH
Phase 3
1,520
Mannheim, Tübingen, Esslingen am Neckar, Freiburg im Breisgau, Amberg, Augsburg, München, Würzburg
2026-04-29
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Berlin, Bonn, Dresden, Düsseldorf, Tübingen
2026-04-17
Recruiting
DEfeating PEnile CAncer-2
NCT07378670Penile Cancer, Penile Neoplasms Malignant
University Hospital Tuebingen
Not applicable
80
Berlin, Dresden, Erlangen, Mainz, Mannheim, München, Rostock, Tübingen
2026-04-10
Recruiting
Hoffmann-La Roche
Phase 2
80
Aachen, Dessau, Essen, Heidelberg, Tübingen
2026-04-07
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Tübingen
2026-04-02
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Tübingen, Oldenburg, Wuppertal, Leipzig
2026-04-01
Recruiting
MELODY Registry Follow-Up Study
NCT06845371Congenital Heart Disease (CHD)
University Hospital Tuebingen
Observational
845
Tübingen
2026-04-01
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Aachen, Bochum, Münster, Tübingen, Ulm
2026-03-24
Recruiting
Santen SAS
Observational
112
Düsseldorf, Tübingen
2026-03-19
Recruiting
AIRNA Corporation
Phase 1
54
Hanover, Tübingen
2026-03-17
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Berlin, Essen, Frankfurt, Freiburg im Breisgau, Hamburg, Hanover, Münster, Tübingen
2026-03-17
Recruiting
Sanaria Inc.
Phase 1
42
Tübingen
2026-03-12
Recruiting
Hoffmann-La Roche
Phase 2
360
Freiburg im Breisgau, Mannheim, Tübingen, Ulm, Erlangen, Munich, Frankfurt am Main, Bochum
2026-03-10
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Ludwigshafen, Bonn, Münster, Tübingen
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Munich, Bad Bentheim, Bielefeld, Hamburg, Hanover, Lübeck, Münster, Tübingen
2026-03-09
Recruiting
University Hospital Schleswig-Holstein
Phase 2
390
Berlin, Kiel, Leipzig, Lübeck, München, Tübingen
2026-03-03
Not yet open
Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI
NCT07411365PARKINSON DISEASE (Disorder), Mild Cognitive Impairment (MCI)
University Hospital Tuebingen
Not applicable
42
Tübingen
2026-03-01
Recruiting
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
NCT07214064AML (Acute Myeloid Leukemia), MDS/AML, MDS (Myelodysplastic Syndrome)
University Hospital Tuebingen
Phase 2
27
Tübingen
2026-02-19
Active, closed
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
NCT07042620Brain Tumor Adult, Low Grade Glioma (LGG), High Grade Glioma (HGG), Glioblastoma
SonoClear AS
Not applicable
15
Günzburg, Marburg, Tübingen, Villingen-Schwenningen
2026-02-09
Recruiting
University Hospital Tuebingen
Phase 2
52
Tübingen
2026-02-01
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
Tübingen, Jena
2026-01-29
Recruiting
IDEAYA Biosciences
Phase 3
520
Tübingen, Ulm, Erlangen, Essen, Dessau, Berlin, Bonn, Lübeck
2026-01-25
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Tübingen, Cologne, Berlin
2026-01-22
Recruiting
Sanofi
Phase 3
751
Tübingen, Ulm, Leipzig, Halle, Kiel, Berlin, Minden
2026-01-16
Active, closed
Kailera
Phase 3
1,270
Tübingen, Falkensee, Cologne, Essen, Oldenburg in Holstein, Schwerin
2026-01-12
Recruiting
University Hospital Tuebingen
Phase 2
100
Tübingen
2026-01-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Göppingen, Stuttgart, Tübingen, Ulm, Donauwörth, München, Regensburg, Traunstein
2026-01-02
Recruiting
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
NCT07299994Stroke, Thrombolysis, DAPT(Dual Antiplatelet Therapy), SAPT(Single Antiplatelet Therapy)
Sigmund Freud PrivatUniversitat
Observational
462
Berlin, Heidelberg, Tübingen
2026-01-01
Active, closed
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
NCT07455097Intermediate-risk Prostate Cancer, High-risk Prostate Cancer
Heinrich-Heine University, Duesseldorf
Observational
600
Düsseldorf, Herne, Munich, Tübingen
2026-01-01
Recruiting
PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGE
NCT07313943Hodgkin or Non-Hodgkin Lymphoma
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
60
Tübingen
2025-12-30
Active, closed
Kailera
Phase 3
2,530
Tübingen, Falkensee, Cologne, Essen, Dresden, Leipzig, Oldenburg in Holstein, Hamburg
2025-12-18
Recruiting
Ascendis Pharma A/S
Phase 3
186
Cologne, Düsseldorf, Hanover, Tübingen
2025-12-12
Active, closed
Boehringer Ingelheim
Phase 3
135
Cologne, Hamburg, Heidelberg, Tübingen
2025-12-09
Recruiting
Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children
NCT07193719Congenital Heart Disease, Cardiopulmonary Bypass, Cardiac Surgery, Mechanical Ventilation
Charite University, Berlin, Germany
Phase 1/2
80
Tübingen
2025-12-05
Recruiting
GlaxoSmithKline
Phase 3
450
München, Cologne, Essen, Dresden, Berlin, Mannheim, Tübingen
2025-12-03
By invitation
University Hospital Tuebingen
Observational
100
Tübingen
2025-12-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Stuttgart, Tübingen, Göttingen, Schwerin, Herne, Münster, Dresden, Erfurt
2025-11-26
Recruiting
Erbe Elektromedizin GmbH
Not applicable
72
Tübingen
2025-11-26
By invitation
Celldex Therapeutics
Phase 3
1,370
Darmstadt, Dülmen, Kiel, Bad Bentheim, Dresden, Mainz, Tübingen
2025-11-25
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Heidelberg, Stuttgart, Tübingen, Braunschweig, Düsseldorf, Herne, Minden, Chemnitz
2025-11-25
Recruiting
Bayer
Phase 3
111
Giessen, Cologne, Tübingen
2025-11-19
Active, closed
Hoffmann-La Roche
Phase 2
193
Berlin, Bochum, Dresden, Tübingen
2025-11-13
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Bonn, Sulzbach, Cologne, Giessen, Mainz, München, Münster, Tübingen
2025-11-10
Recruiting
AbbVie
Phase 3
561
Freiburg im Breisgau, Tübingen, Ulm, Munich, Göttingen, Hanover, Bonn, Münster
2025-11-05
Recruiting
University Hospital Tuebingen
Phase 3
150
Saarlouis, Berlin, Bottrop, Dresden, Marburg, Tübingen, Wolfach
2025-10-27
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Bielefeld, Tübingen
2025-10-27
Recruiting
Abalos Therapeutics GmbH
Phase 1
27
Berlin, Tübingen
2025-10-14
Active, closed
Sanofi
Phase 2
60
Frankfurt, Ludwigshafen, Tübingen, Ulm
2025-10-14
Recruiting
Genentech, Inc.
Phase 1/2
285
Tübingen, Hanover, Essen, Dresden, Hamburg, Heidelberg
2025-10-07
Recruiting
Sanofi
Phase 3
980
Tübingen, Ulm, Würzburg, Remscheid, Ludwigshafen am Rhein, Dresden, Leipzig, Halle
2025-10-01
Recruiting
Natural History of Type 1 Interferonopathies: Insights From a European Cohort
NCT07040774Genetic Disease, Immune Dysfunction, Neurological Diseases or Conditions, Autoimmune Diseases
Imagine Institute
Observational
500
Tübingen
2025-10-01
Not yet open
Medical University Innsbruck
Not applicable
80
Berlin, Freiburg im Breisgau, Göttingen, München, Münster, Tübingen
2025-09-30
Recruiting
Clinical Course Of Disease In Participants With FA-CM
NCT06865482Friedreich Ataxia, Cardiomyopathy
Lexeo Therapeutics
Observational
65
Tübingen
2025-09-30
Recruiting
Alfasigma S.p.A.
Phase 3
80
Aachen, Leipzig, Mainz, Tübingen
2025-09-29
Recruiting
SINEFIX-2022 Comparative Phase
NCT06818448Rotator Cuff Tears of the Shoulder
BAAT Medical Products B.V.
Not applicable
60
Mechernich, Tübingen
2025-09-16
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Tübingen
2025-08-28
Recruiting
BioNTech SE
Phase 1/2
1,438
Berlin, Essen, Mainz, München, Tübingen
2025-08-12
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
34
Erfurt, Erlangen, Heidelberg, Leipzig, Minden, Oberhausen, Regensburg, Tübingen
2025-08-07
Active, closed
Boehringer Ingelheim
Phase 1
16
Dresden, Hanover, Tübingen
2025-07-29
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Berlin, Erlangen, Essen, Mainz, Marburg, Tübingen, Würzburg
2025-07-21
Recruiting
Michael Dill
Phase 2
48
Heidelberg, Augsburg, Essen, Mannheim, Regensburg, Tübingen, Ulm
2025-07-16
Recruiting
University Hospital Tuebingen
Phase 1
20
Tübingen
2025-07-08
Recruiting
Anocca AB
Phase 1/2
96
Berlin, Dresden, Heidelberg, Leipzig, München, Tübingen
2025-07-03
Recruiting
Long-Term Cognitive Recovery After Arteria Cerebri Media Ischemia: A Digital Assessment Using the TuCAN-App
NCT07885189Cognitive Recovery After Stroke, Cognitive Outcome After Stroke
University Hospital Tuebingen
Observational
50
Tübingen
2025-07-01
Recruiting
Ipsen
Phase 2
132
Haag in Oberbayern, Hamburg, Troisdorf, Tübingen
2025-06-30
Recruiting
A Phase I Dose Finding Study of MB-CART2219.1
NCT07108868Lymphoma, CLL, Acute Lymphoblastic Leukemia, Pediatric
University Hospital Tuebingen
Phase 1
36
Tübingen
2025-06-23
Recruiting
BioNTech SE
Phase 3
480
Berlin, Essen, Kassel, München, Tübingen
2025-06-10
Recruiting
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT06891443Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
DrugSepofarsen
Laboratoires Thea
Phase 3
32
Giessen, München, Tübingen
2025-06-04
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Berlin, Dresden, Frankfurt am Main, Hanover, Mainz, Tübingen
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 2
144
Tübingen, Berlin
2025-05-28
Recruiting
Swedish Orphan Biovitrum
Phase 2
156
Tübingen, Munich, Hamburg, Düsseldorf, Dresden, Lübeck
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Tübingen, Cologne, Münster
2025-05-26
Recruiting
Eikon Therapeutics
Phase 2/3
740
Mannheim, Tübingen, Würzburg, Erlangen, Martinsried, Haus, Buxtehude, Minden
2025-05-22
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
44
Dresden, Berlin, Mainz, Tübingen
2025-05-22
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main
2025-05-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
96
Tübingen, Berlin
2025-05-13
Recruiting
Joseph Broderick, MD
Phase 3
350
Heidelberg, Erlangen, Frankfurt am Main, Augsburg, Berlin, Hamburg, Tübingen
2025-05-06
Recruiting
Safety of HRX215 in Patients After Minor and Major Liver Resection
NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases
HepaRegeniX GmbH
Phase 1/2
80
Essen, Tübingen
2025-05-06
Recruiting
AbbVie
Observational
125
Allensbach, Heidelberg, Tübingen, Ulm, Wolfach, Erlangen, Ingolstadt, Munich
2025-05-05
Recruiting
Anesthesia Induced Myocardial Injury in Non-cardiac Surgery (AIMY)
NCT07179029Perioperative Myocardial Injury
University Hospital Tuebingen
Observational
3,000
Tübingen
2025-05-01
Recruiting
Brain Signal Training to Enhance Affect Down-regulation
NCT06626789Borderline Personality Disorder
Central Institute of Mental Health, Mannheim
Phase 1/2
164
Freiburg im Breisgau, Giessen, Halle, Hamburg, Mannheim, Tübingen
2025-04-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Stuttgart, Tübingen, Ulm, Erlangen, Munich, Würzburg, Frankfurt am Main, Kassel
2025-04-11
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Göttingen, Münster, Tübingen
2025-04-01
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Berlin, Bochum, Essen, Tübingen, Ulm, Würzburg
2025-03-18
Recruiting
UCB Biopharma SRL
Phase 3
40
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Sankt Augustin, Sendenhorst, Tübingen
2025-03-11
Recruiting
University Hospital Tuebingen
Not applicable
508
Tübingen
2025-03-01
Recruiting
Integrum
Not applicable
70
Hanover, Tübingen
2025-02-19
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
56
Tübingen, Erlangen, Oldenburg, Bochum
2025-02-19
Active, closed
Sanofi
Phase 3
231
Berlin, Frankfurt, Hamburg, Landsberg, Münster, Tübingen, Wiesbaden, Würzburg
2025-02-12
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Berlin, Giessen, Hanover, Jena, Tübingen
2025-02-10
Recruiting
LEO Pharma
Phase 3
90
Berlin, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg
2025-02-05
Recruiting
LEOPARD Training and Validation Data Collection Study
NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
Assistance Publique - Hôpitaux de Paris
Observational
4,500
Aachen, Berlin, Hanover, Jena, Kiel, Leipzig, Münster, Tübingen
2025-02-04
Not yet open
Department of Trauma and Reconstructive Surgery at Eberhard Karls University Tuebingen, BG Klinik Tu
Observational
2,300
Tübingen
2025-02-01
Not yet open
Radboud University Medical Center
Phase 2/3
20
Tübingen
2025-02
Active, closed
Definium Therapeutics US, Inc.
Phase 3
245
Berlin, Mannheim, Tübingen
2025-01-29
Active, closed
argenx
Phase 3
631
Tübingen, Munich, Hamburg, Hanover
2025-01-15
Recruiting
Galimedix Therapeutics Inc
Phase 2
110
Bonn, Freiburg im Breisgau, Hanover, Neubrandenburg, Tübingen, Ulm
2025-01-10
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Augsburg, Tübingen, Erlangen, Mahlow, Darmstadt, Frankfurt am Main, Bad Bentheim, Bramsche
2025-01-08
Recruiting
Fondation Hôpital Saint-Joseph
Observational
2,000
Tübingen
2025-01-01
Active, closed
Boehringer Ingelheim
Phase 2
90
Berlin, Tübingen
2024-12-30
Recruiting
Biotronik AG
Observational
200
Arnsberg, Berlin, Tübingen
2024-12-19
Active, closed
Arrowhead Pharmaceuticals
Phase 1
39
Tübingen, Ulm
2024-12-17
Recruiting
Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation
NCT06709833Meningeoma, Thrombembolism, Surgical Resection
University Hospital Tuebingen
Observational
100
Tübingen
2024-12-16
Recruiting
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
NCT06201234Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
DrugsElacestrant·Olaparib
GBG Forschungs GmbH
Phase 2
176
Stuttgart, Tübingen, Winnenden, Weinheim, Augsburg, Bayreuth, Fürstenwalde, Frankfurt am Main
2024-12-13
Recruiting
Biogen
Observational
300
Tübingen, Aachen, Munich
2024-12-12
Active, closed
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
Laboratoires Thea
Phase 2
81
Tübingen
2024-12-11
By invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Tübingen, Erlangen, Sachsen, Göttingen, Lübeck
2024-12-09
Active, closed
Vicore Pharma AB
Phase 2
378
Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Immenhausen, Hanover, Essen, Berlin
2024-12-09
Active, closed
H. Lundbeck A/S
Phase 3
401
Tübingen, Erlangen, Haag I.Ob, Munich, Münster, Beelitz-Heilstätten
2024-12-03
Active, closed
AstraZeneca
Phase 3
181
Marburg, Tübingen, Villingen-Schwenningen, Wiesbaden
2024-12-03
Recruiting
BeOne Medicines
Phase 1/2
80
Dresden, Jena, Kiel, Tübingen, Ulm
2024-11-27
Active, closed
AbbVie
Observational
1,314
Heidelberg, Tübingen, Hoppegarten, Bad Homburg, Oldenburg, Greifswald, Siegen, Velbert
2024-11-26
Active, closed
Novartis Pharmaceuticals
Phase 4
24
Munich, Bochum, Hamburg, Tübingen
2024-11-25
Recruiting
Washington University School of Medicine
Phase 2/3
280
Tübingen, Munich
2024-11-22
Recruiting
Washington University School of Medicine
Phase 2/3
280
Tübingen, Munich
2024-11-22
By invitation
Study on the Effectiveness of Journaling as an add-on to Cognitive Behavioral Therapy
NCT06863909Affective Disorders, Rumination, Childhood Trauma, Eating Disorder
University Hospital Tuebingen
Not applicable
80
Tübingen
2024-11-20
Active, closed
argenx
Phase 2
87
Bad Bramstedt, Lübeck, Minden, Tübingen
2024-11-11
Recruiting
AbbVie
Observational
678
Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Amberg, Augsburg, Bamberg, Erlangen
2024-11-07
Recruiting
Investigation of TVNS Administration on Postpartum Mental Health
NCT06682689Postpartum Depression (PPD), Postpartum Anxiety, Postpartum Sadness, Postpartum Blues
University Hospital Tuebingen
Not applicable
120
Tübingen
2024-11
Active, closed
Denali Therapeutics Inc.
Phase 2
50
Dresden, Lübeck, Tübingen
2024-10-24
Recruiting
Pfizer
Phase 3
900
Nürtingen, Tübingen, Münster, Hamburg
2024-10-22
Active, closed
Pfizer
Phase 3
609
Nürtingen, Tübingen, Mettmann, Münster, Hamburg
2024-10-21
Recruiting
Women's Cancer Study Group GmbH
Phase 3
348
Baden-Baden, Böblingen, Freiburg im Breisgau, Heilbronn, Tübingen, Ulm, Weinheim, Augsburg
2024-10-10
By invitation
Impact of Energy Density on Energy Intake During Bed Rest
NCT06571877Bed Rest, Space Analogue
University Hospital Tuebingen
Not applicable
48
Tübingen
2024-09-24
Recruiting
Janssen Research & Development, LLC
Phase 2/3
274
Bonn, Göttingen, Hanover, Leipzig, Ludwigshafen am Rhein, Münster, Tübingen
2024-09-19
Recruiting
European Registry of Next Generation Imaging in Advanced Prostate Cancer
NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
Fundacio Puigvert
Observational
600
Bonn, Hamburg, Munich, Planegg, Tübingen
2024-09-17
Recruiting
University Hospital Tuebingen
Not applicable
106
Tübingen
2024-09-15
Recruiting
University Hospital Tuebingen
Not applicable
264
Tübingen
2024-09-11
Active, closed
Kite, A Gilead Company
Phase 3
452
Berlin, Cologne, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Tübingen
2024-08-23
Active, closed
Janssen Research & Development, LLC
Phase 2
43
Heidelberg, Tübingen, Würzburg
2024-08-20
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Tübingen, Erlangen, Rüdersdorf, Sachsen, Göttingen, Lübeck
2024-08-19
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Tübingen, Cologne, Münster, Berlin
2024-08-16
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
Erlangen, Essen, München, Tübingen
2024-08-14
Recruiting
MB-CART19.1 in Refractory SLE
NCT06189157SLE - Systemic Lupus Erythematosus
DrugMB-CART19.1
Miltenyi Biomedicine GmbH
Phase 1/2
29
Erlangen, Magdeburg, Tübingen
2024-08-12
Active, closed
Annexon, Inc.
Phase 3
659
Neubrandenburg, Münster, Bonn, Heidelberg, Tübingen
2024-07-30
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Freiburg im Breisgau, Heidelberg, Tübingen, München, Frankfurt am Main, Hanover, Dresden, Lübeck
2024-07-19
Active, closed
University Hospital Tuebingen
Not applicable
120
Tübingen
2024-07-19
Recruiting
Hannover Medical School
Not applicable
756
Ludwigsburg, Tübingen, Bad Homburg, Göttingen, Hanover, Lüneburg, Bielefeld, Düsseldorf
2024-07-17
Recruiting
Pamgene International B.V.
Observational
196
Tübingen, Heidelberg, München
2024-07-12
Recruiting
Philogen S.p.A.
Phase 2
162
Essen, Freiburg im Breisgau, Kiel, Tübingen
2024-07-12
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Bad Homburg, Berlin, Bochum, Essen, Giessen, Tübingen
2024-07-12
Recruiting
University Hospital Tuebingen
Phase 1
52
Tübingen
2024-07-10
Recruiting
University Hospital Tuebingen
Not applicable
50
Tübingen
2024-07-01
Recruiting
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
NCT06487832Normal Weight, Overweight and Obesity, Insulin Sensitivity, Insulin Resistance
University Hospital Tuebingen
Not applicable
60
Tübingen
2024-07-01
Active, closed
AbbVie
Phase 3
1,400
Freiburg im Breisgau, Tübingen, Erlangen, Memmingen, Darmstadt, Bad Bentheim, Rostock, Bochum
2024-06-27
Recruiting
Non Interventional German Leptomeningeal Disease Register
NCT06146010Meningeal Neoplasms, Leptomeningeal Disease
University Hospital Tuebingen
Observational
50
Bonn, Mannheim, München, Münster, Siegen, Tübingen, Ulm
2024-06-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Freiburg im Breisgau, Ludwigsburg, Tübingen, Erlangen, Munich, Potsdam, Georgsmarienhütte, Hanover
2024-06-24
Recruiting
AstraZeneca
Phase 3
240
Bad Nauheim, Berlin, Bonn, Freiburg im Breisgau, Herne, München, Tübingen
2024-06-20
Active, closed
Ivy Brain Tumor Center
Phase 3
450
Heidelberg, Mannheim, Tübingen, Regensburg, Bonn, Chemnitz, Leipzig, Berlin
2024-06-19
Active, closed
AskBio Inc
Phase 2
59
Berlin, Marburg, Tübingen, Würzburg
2024-06-11
Recruiting
LEO Pharma
Phase 3
195
Buxtehude, Dresden, Mainz, Osnabrück, Tübingen, Wuppertal
2024-06-10
Recruiting
University Hospital Tuebingen
Phase 1
20
Tübingen
2024-06-10
Recruiting
Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS)
NCT06472557Spinocerebellar Ataxia Type 27B
University Hospital Tuebingen
Observational
300
Tübingen, Essen
2024-06-04
Recruiting
Lohmann & Rauscher
Observational
110
Berlin, Mannheim, Munich, Münster, Rheine, Tübingen
2024-06-03
Recruiting
Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure
NCT07016477Coronary Artery Disease, Aortic Valve Stenosis, Tomography, X-Ray Computed
Semmelweis University
Observational
1,000
Freiburg im Breisgau, Mainz, Tübingen
2024-06-01
Recruiting
Long-term Follow-up of Children Born in the PETN Studies
NCT06534307Intrauterine Growth Restriction, Pentaerithrityl Teratnitrate in Pregnancy, Long-Term Effects to Children
Jena University Hospital
Observational
228
Tübingen, Ulm, München, Hanover, Bonn, Dresden, Leipzig, Halle
2024-06-01
Recruiting
University Hospital Tuebingen
Observational
225
Tübingen
2024-06-01
Active, closed
Stealth BioTherapeutics Inc.
Phase 3
313
Münster, Regensburg, Tübingen
2024-05-30
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
220
Heidelberg, Tübingen, Munich, Berlin, Hamburg
2024-05-20
Recruiting
Boehringer Ingelheim
Phase 2
175
Bonn, Mainz, Neubrandenburg, Tübingen, Ulm
2024-05-15
Recruiting
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
DrugsMB-CART19.1·Zamtocabtagene autoleucel
Miltenyi Biomedicine GmbH
Not applicable
40
Berlin, Cologne, Erlangen, Göttingen, Münster, Tübingen, Würzburg
2024-05-05
Recruiting
University Hospital Tuebingen
Phase 2
60
Tübingen, Jena
2024-04-29
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main
2024-04-29
Active, closed
Takeda
Phase 2
213
Frankfurt am Main, Hamburg, Heidelberg, Kiel, Ludwigshafen, Tübingen, Ulm
2024-03-29
Recruiting
Splice Bio
Observational
75
Bonn, Tübingen
2024-03-29
Recruiting
Negative Emotionality and Epigenetics During Puberty
NCT06690866Puberty, Healthy, Stress
International Research Training Group 2804
Observational
100
Tübingen
2024-03-26
Recruiting
The NEU-STIM Trial
NCT05942924Infant, Premature, Diseases, Birth, Preterm
Leiden University Medical Center
Not applicable
3,280
Dresden, Düsseldorf, Tübingen
2024-03-11
Recruiting
Takeda
Phase 2
268
Frankfurt, Frankfurt am Main, Kiel, Ludwigshafen, Mannheim, Tübingen, Ulm
2024-03-05
Recruiting
Takeda
Phase 3
50
Aachen, Berlin, Hanover, Tübingen
2024-03-01
Recruiting
University Hospital Muenster
Observational
2,000
Chemnitz, Aachen, Greifswald, Leipzig, Münster, Tübingen
2024-03-01
By invitation
Christian Dorfer
Observational
100
Berlin, Tübingen
2024-03-01
Active, closed
Terumo Europe N.V.
Not applicable
50
Heilbronn, Tübingen
2024-02-27
Recruiting
Electrosurgical Intervention Analysis: Comparing Procedure Patterns
NCT06873347Surgical Procedure, Unspecified
University Hospital Tuebingen
Observational
160
Tübingen
2024-02-21
Recruiting
AI-Based Real-Time Detection of Surgical Smoke Using Endoscopic Data
NCT07397000Detection of Surgical Smoke Gas Using AI
University Hospital Tuebingen
Observational
30
Tübingen
2024-02-21
Recruiting
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
NCT06134492Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex
DrugAcyclovir
Jena University Hospital
Phase 3
616
Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Nuremberg, Regensburg, Rosenheim
2024-02-20
Recruiting
Oxytocin and Reward Processing in Women
NCT06222749Menstrual Cycle, Hormonal Contraception
DrugOxytocin
International Research Training Group 2804
Not applicable
100
Tübingen
2024-02-16
Active, closed
Boehringer Ingelheim
Phase 3
428
Augsburg, Berlin, Cologne, Dresden, Giessen, Heidelberg, Oldenburg, Tübingen
2024-02-09
Recruiting
Women's Cancer Study Group GmbH
Phase 2
702
Baden-Baden, Freiburg im Breisgau, Tübingen, Ulm, Augsburg, Munich, Bremerhaven, Frankfurt am Main
2024-02-05
Recruiting
University Hospital Tuebingen
Not applicable
120
Tübingen
2024-01-31
Recruiting
Boehringer Ingelheim
Phase 1
20
Frankfurt, München, Tübingen
2024-01-30
Recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
NCT06835218Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
UroTrials Company (GmbH)
Observational
5,000
Freiburg im Breisgau, Heidelberg, Mannheim, Nürtingen, Tübingen, Ulm, Augsburg, Bayreuth
2024-01-29
Active, closed
Boehringer Ingelheim
Phase 1
65
München, Tübingen
2024-01-22
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Augsburg, Halle, Heidelberg, Magdeburg, München, Tübingen, Würzburg
2024-01-22
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
98
Bonn, Tübingen
2024-01-16
Recruiting
FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
NCT05999396Colorectal Cancer, Breast Carcinoma, Sarcoma, Penile Carcinoma
German Cancer Research Center
Phase 1
89
Tübingen
2024-01-12
Recruiting
University Hospital Tuebingen
Observational
75
Tübingen
2024-01-04
Recruiting
Insel Gruppe AG, University Hospital Bern
Observational
2,800
Sanderbusch, Tübingen
2024-01-01
Recruiting
University Hospital Tuebingen
Observational
50
Tübingen
2023-12-27
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Göttingen, Stade, Dresden, Berlin, Mainz, Münster, Tübingen
2023-12-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Heilbronn, Mannheim, Ravensburg, Tübingen, Munich, Essen, Dresden, Berlin
2023-12-06
Recruiting
AstraZeneca
Phase 1/2
226
Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg
2023-12-05
Not yet open
Initiative for Clinical Long-read Sequencing
NCT06060184Genetic Predisposition
University Hospital Tuebingen
Not applicable
500
Tübingen
2023-12-01
Recruiting
University Hospital Heidelberg
Not applicable
2,500
Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Mainz, Dresden, Berlin
2023-12-01
Active, closed
Gyrate Atrophy Ocular and Systemic Study
NCT05312736Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy, Ornithine-δ-aminotransferase, OAT
Jaeb Center for Health Research
Observational
46
Tübingen
2023-11-21
Active, closed
University Hospital Tuebingen
Observational
40
Tübingen
2023-11-17
Active, closed
AbbVie
Phase 2
280
Mannheim, Tübingen, Ulm, Dresden, Berlin, Hamburg
2023-11-12
Active, closed
AstraZeneca
Phase 3
314
Freiburg im Breisgau, Mainz, Minden, Münster, Tübingen
2023-11-08
Recruiting
University Hospital Tuebingen
Phase 2
27
Tübingen
2023-11-04
Recruiting
CeraFlex PFO Closure System PMCF Study
NCT06120270Patent Foramen Ovale
Lifetech Scientific (Shenzhen) Co., Ltd.
Observational
180
Bremen, Dresden, Fürth, Hamburg, Leipzig, Munich, Trier, Tübingen
2023-11-03
Recruiting
University Hospital Tuebingen
Phase 4
170
Berlin, Dresden, Düsseldorf, Heidelberg, Leipzig, Lübeck, München, Tübingen
2023-10-26
Recruiting
Exercise Training on Brain Insulin Responsiveness
NCT06039787Insulin Resistance, Obesity
University Hospital Tuebingen
Not applicable
40
Tübingen
2023-10-20
Active, closed
Johns Hopkins University
Phase 3
485
Tübingen
2023-10-11
Active, closed
Stichting European Myeloma Network
Phase 3
759
Cologne, Hamburg, Leipzig, Tübingen, Würzburg
2023-10-10
Recruiting
Fracture Monitor - Femur
NCT05410587Femoral Fracture
AO Innovation Translation Center
Not applicable
37
Homburg, Münster, Tübingen, Ulm
2023-10-03
Recruiting
Universität Münster
Not applicable
165
Münster, Tübingen
2023-10-02
Recruiting
University Hospital Tuebingen
Phase 1
20
Tübingen
2023-09-26
Active, closed
PharmaMar
Phase 3
469
München, Bad Saarow, Dresden, Hanover, Heidelberg, Manheim, Münster, Tübingen
2023-09-21
Recruiting
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
NCT06094101Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma
University Hospital Tuebingen
Phase 1/2
30
Essen, Frankfurt am Main, Freiburg im Breisgau, Tübingen
2023-09-19
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Tübingen, Lübeck, Hamburg, Leipzig
2023-09-18
Active, closed
Hoffmann-La Roche
Phase 3
687
Esslingen am Neckar, Magdeburg, Mainz, Tübingen
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Minden, Mainz, Cologne, Düsseldorf, Tübingen
2023-09-13
By invitation
argenx
Phase 3
240
Berlin, Hamburg, Herne, Mannheim, Tübingen, Ulm
2023-09-12
Recruiting
Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
NCT05914974Gynecological Malignancies, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
University Hospital Tuebingen
Observational
120
Tübingen
2023-09-11
Active, closed
Bristol-Myers Squibb
Phase 3
774
Munich, Berlin, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg
2023-09-11
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
Bad Oeynhausen, Bremen, Hanover, Stuttgart, Tübingen
2023-09-01
Recruiting
VeonGen Therapeutics GmbH
Phase 1
6
Tübingen
2023-09-01
Active, closed
Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)
NCT07579390Acute Kidney Failure, Renal Replacement Therapy for Acute Kidney Injury in ICU, Sedation in Intensive Care Unit Patients, Sedation in the ICU
Helsinki University Central Hospital
Not applicable
3,500
Berlin, Lübeck, Tübingen
2023-08-17
Active, closed
Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation
NCT05564754Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
Region Skane
Not applicable
3,500
Berlin, Lübeck, Tübingen
2023-08-17
Recruiting
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
NCT05958121Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Immatics Biotechnologies GmbH
Phase 1/2
400
Heidelberg, Mannheim, Tübingen, Ulm, Erlangen, Nuremberg, Regensburg, Würzburg
2023-08-09
Recruiting
Stepcare Extended Follow-up Substudy
NCT06207942Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain, Cognitive Impairment, Caregiver Burden
Region Skane
Not applicable
600
Berlin, Lübeck, Tübingen
2023-08-01
Active, closed
Novartis Pharmaceuticals
Phase 3
100
Frankfurt am Main, Berlin, Tübingen
2023-07-11
Recruiting
German Cancer Research Center
Phase 2
240
Heidelberg, Tübingen, Augsburg, Erlangen, Ulm, Würzburg, Dresden, Berlin
2023-06-29
Recruiting
Friedreich's Ataxia Research Alliance
Observational
3,000
Aachen, Bonn, Munich, Tübingen
2023-06-28
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
36
Tübingen
2023-06-27
Recruiting
University Hospital Tuebingen
Not applicable
150
Tübingen
2023-06-02
Recruiting
German Center for Neurodegenerative Diseases (DZNE)
Observational
200
Aachen, Bonn, Münich, Tübingen
2023-06-01
Recruiting
University Hospital Tuebingen
Phase 1/2
60
Tübingen
2023-04-27
Recruiting
University Hospital Tuebingen
Observational
504
Tübingen
2023-04-25
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Cottbus, Dresden, Greifswald, Hamburg, Heidelberg, Marburg, Tübingen, Ulm
2023-03-29
Recruiting
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
NCT05366218ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory
DrugTafasitamab
University Hospital Tuebingen
Phase 1/2
20
Freiburg im Breisgau, Tübingen, Ulm, München, Hamburg, Düsseldorf, Berlin, Essen
2023-03-08
Recruiting
Takeda
Phase 3
160
Aachen, Berlin, Hanover, Kiel, Tübingen
2023-03-06
Active, closed
University Hospital Tuebingen
Not applicable
90
Tübingen
2023-03-01
Active, closed
German Cancer Research Center
Phase 1
15
Heidelberg, Mannheim, Tübingen, Frankfurt am Main, Bonn, Essen, Dresden, Berlin
2023-02-15
Recruiting
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
NCT05822908Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Vico Therapeutics B. V.
Phase 1/2
68
Bochum, Bonn, Essen, Tübingen
2023-02-14
Recruiting
University Hospital Tuebingen
Not applicable
144
Frankfurt a.M., Cologne, Münster, Tübingen
2023-02-06
Recruiting
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
NCT05492682Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma
DrugsCyclophosphamide·Pembrolizumab
Valo Therapeutics Oy
Phase 1
15
Frankfurt, Heidelberg, Tübingen
2023-02-02
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Mannheim, Tübingen, Augsburg, Erlangen, Munich, Regensburg, Darmstadt, Frankfurt am Main
2023-01-16
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Freiburg im Breisgau, Heidelberg, Nürtingen, Pforzheim, Tübingen, Ulm, Erlangen, Munich
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
516
Tübingen, Munich, Dresden, Lübeck, Chemnitz, Cologne, Erlangen, Planegg
2023-01-12
Recruiting
Eli Lilly and Company
Phase 1
677
Bonn, München, Tübingen
2023-01-12
Recruiting
University Hospital Tuebingen
Observational
10,000
Tübingen
2023-01-11
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
247
Kiel, Tübingen, Ulm, Wipperfürth
2023-01-11
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
Tübingen, Frankfurt am Main, Arnsberg, Leipzig, Berlin, Augsburg, Heidelberg
2023-01-06
Recruiting
Inflammation During ECMO Therapy and ECMO Weaning
NCT05640635Acute Respiratory Distress Syndrome
University Hospital Tuebingen
Not applicable
40
Tübingen
2023-01-01
Active, closed
Janssen Research & Development, LLC
Phase 3
214
Chemnitz, Hamburg, Tübingen
2022-12-15
Active, closed
PTC Therapeutics
Phase 3
130
Tübingen
2022-12-08
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Kempten (Allgäu), Halle, Hamburg, Oldenburg, Tübingen
2022-12-06
Recruiting
Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
NCT06621810Melanoma (Skin Cancer), Artificial Intelligence (AI), Pediatric Cancer
German Cancer Research Center
Observational
3,000
Tübingen
2022-12-01
Active, closed
SELUTION4SFA Trial
NCT05132361Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
M.A. Med Alliance S.A.
Not applicable
300
Arnsberg, Bad Krozingen, Buchholz, Coburg, Leipzig, Rosenheim, Tübingen
2022-12-01
Recruiting
Molecular Inflammation Board at the Center for Personalized Medicine
NCT07132333Psoriasis (PsO), Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Spondylarthropathies
University Hospital Tuebingen
Observational
3,000
Tübingen
2022-11-16
Recruiting
University Hospital Tuebingen
Phase 1
56
Tübingen
2022-11-11
Recruiting
Pfizer
Phase 3
1,060
Freiburg im Breisgau, Tübingen, Ulm, Mainz, Aachen, Braunschweig, Chemnitz, Hamburg
2022-11-10
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Berlin, Essen, Halle, Hamburg, Nuremberg, Tübingen, Würzburg
2022-10-25
Active, closed
AbbVie
Phase 1
283
Tübingen, Regensburg, Würzburg, Essen, Hamburg
2022-10-20
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
Mannheim, Tübingen, Frankfurt am Main, Hanover, Aachen, Bergisch Gladbach, Bonn, Essen
2022-10-14
Recruiting
University of Zurich
Phase 2
276
Tübingen
2022-09-22
Active, closed
Genmab
Phase 3
549
Tübingen, Würzburg, Giessen, Kassel, Göttingen, Bonn, Dresden, Leipzig
2022-09-20
Active, closed
Vir Biotechnology, Inc.
Phase 2
95
Frankfurt, Hanover, Tübingen
2022-09-17
Active, closed
Biogen
Phase 2/3
450
Heidelberg, Tübingen, Erlangen, Munich, Regensburg, Würzburg, Bad Bentheim, Buxtehude
2022-09-13
Recruiting
AO Innovation Translation Center
Observational
300
Tübingen, Aachen, Berlin, Hanover, Heidelberg, Leipzig, Munich, Ulm
2022-09-12
Active, closed
European Myeloma Network B.V.
Phase 3
1,594
Hamburg, Heidelberg, Jena, Lübeck, München, Nuremberg, Tübingen, Würzburg
2022-09-08
Active, closed
Biogen
Phase 2
416
Mannheim, Tübingen, Ulm, Bayreuth, München, Erbach im Odenwald, Göttingen, Bonn
2022-08-24
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 2
256
Muenchen, Halle, Essen, Frankfurt, Mönchengladbach, Münster, Tübingen
2022-08-17
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
Dresden, Berlin, Hamburg, Tübingen, Weiden
2022-08-08
Active, closed
Institut fuer Frauengesundheit
Phase 2
11
Tübingen, Ulm, Erlangen, Bottrop, Düsseldorf, Berlin
2022-07-30
Recruiting
Otoferlin Gene-mediated Hearing Loss Natural History Study
NCT05572073Sensorineural Hearing Loss, Bilateral
Akouos, Inc.
Observational
150
Tübingen
2022-07-14
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,546
Mannheim, Tübingen, Munich, Nuremberg, Regensburg, Frankfurt am Main, Giessen, Buxtehude
2022-07-14
By invitation
Gyroscope Therapeutics Limited
Phase 2
225
Lübeck, Tübingen
2022-07-12
Active, closed
Albireo, an Ipsen Company
Phase 3
180
Berlin, Tübingen
2022-07-05
Recruiting
Pfizer
Phase 4
210
Tübingen, Magdeburg, Berlin
2022-07-05
Active, closed
University Hospital Tuebingen
Phase 1
96
Tübingen, Hamburg
2022-06-24
Active, closed
University Hospital Heidelberg
Not applicable
30
Tübingen, Münich, Heidelberg
2022-06-23
Active, closed
Genentech, Inc.
Observational
400
Bonn, Freiburg im Breisgau, Göttingen, Hanover, Leipzig, Münster, Tübingen
2022-05-27
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Dresden, Duisburg, Hamburg, Hanover, München, Tübingen
2022-05-23
Active, closed
Immatics Biotechnologies GmbH
Phase 1
95
Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Erlangen, Munich, Nuremberg, Regensburg
2022-05-19
Recruiting
SELUTION4BTK Trial
NCT05055297Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
M.A. Med Alliance S.A.
Not applicable
376
Arnsberg, Bad Krozingen, Buchholz, Coburg, Essen, Tübingen
2022-05-19
Recruiting
German Dementia Registry
NCT07433010Dementia Disorder
RWTH Aachen University
Observational
5,000
Heidelberg, Mannheim, Tübingen, Ulm, Erlangen, Frankfurt (Oder), Rüdersdorf, Hamburg
2022-05-16
Active, closed
Hoffmann-La Roche
Phase 3
1,300
Tübingen, Ulm, Bayreuth, Munich, Westerstede, Düsseldorf, Chemnitz, Leipzig
2022-05-03
Active, closed
Eli Lilly and Company
Phase 3
925
Freiburg im Breisgau, Heidelberg, Nürtingen, Ulm, Tübingen, Munich, Frankfurt am Main, Duisburg
2022-04-14
Recruiting
Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry
NCT04829175Stress Urinary Incontinence, Pelvic Organ Prolapse
Ethicon, Inc.
Observational
1,000
Tübingen
2022-04-11
Active, closed
Abbott Medical Devices
Not applicable
100
Tübingen, Düsseldorf, Mainz
2022-03-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Singen, Tübingen, Munich, Aachen, Bonn, Düsseldorf, Essen, Münster
2022-03-15
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
18
Hamburg, Tübingen
2022-03-03
Active, closed
Jena University Hospital
Not applicable
230
Tübingen, Hamburg, Bad Oeynhausen, Bad Krozingen, Brandenburg, Coburg, Flensburg, Heidelberg
2022-02-10
Active, closed
AstraZeneca
Phase 1/2
36
Hamburg, München, Tübingen
2022-01-21
Active, closed
Belimumab in Patients with Chronic Lymphocytic Leukemia
NCT05069051Chronic Lymphoid Leukemia in Relapse
DrugBelimumab
University Hospital Tuebingen
Phase 2
120
Tübingen
2022-01-19
Active, closed
Washington University School of Medicine
Phase 2/3
197
Tübingen, Munich
2021-12-22
Active, closed
Goethe University
Phase 1/2
30
Tübingen, Ulm, Frankfurt am Main, Dresden, Berlin, Cologne, Düsseldorf, Erlangen
2021-12-15
Recruiting
RFC1 Natural History Study
NCT05177809Ataxia
Prof. Dr. Matthis Synofzik
Observational
150
Tübingen, Bonn, Lübeck
2021-12-14
Active, closed
Joseph Broderick, MD
Phase 3
860
Heidelberg, Frankfurt am Main, Augsburg, Berlin, Tübingen
2021-12-03
Recruiting
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
NCT04996433Persistent Depressive Disorder, Treatment-resistant Depression
University of Greifswald
Not applicable
396
Berlin, Bonn, Hanover, Jena, Lübeck, Marburg, München, Tübingen
2021-12-01
Active, closed
AbbVie
Observational
338
Baden-Baden, Heidelberg, Stuttgart, Tübingen, Ulm, Hoppegarten, Potsdam, Bruchhausen-Vilsen
2021-11-22
Active, closed
AstraZeneca
Phase 3
145
Hamburg, Tübingen, Würzburg
2021-11-19
Active, closed
Enhancing Brain Health by TDCS in Persons with Overweight and Obesity
NCT05228067Insulin Resistance, Obesity, Diabetes Type 2
University Hospital Tuebingen
Not applicable
40
Tübingen
2021-11-08
Active, closed
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
NCT07280377Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
DrugsPelareorep·Gemcitabine and nab-paclitaxel·Lonsurf·Trifluridine/Tipiracil
Oncolytics Biotech
Phase 1/2
122
Heidelberg, Heilbronn, Tübingen, Ulm, Augsburg, München, Hamburg, Frankfurt am Main
2021-10-27
Recruiting
University Hospital Tuebingen
Phase 1
46
Bonn, Freiburg im Breisgau, Heidelberg, Heilbronn, Mannheim, München, Stuttgart, Tübingen
2021-10-12
Active, closed
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
NCT04907240Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms
W.L.Gore & Associates
Observational
614
Frankfurt, Hamburg, Heidelberg, Reinbek, Tübingen
2021-10-09
Active, closed
Plasma On Chronic Wounds for Epidermal Regeneration
NCT05855499Chronic Ulcer of Lower Extremity
Coldplasmatech
Not applicable
120
Tübingen, München, Regensburg, Hamburg, Bochum, Dresden, Berlin, Saalfeld
2021-10-01
Active, closed
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075Conventional Chondrosarcoma
DrugINBRX-109
Inhibrx Biosciences, Inc
Phase 2
206
Berlin, Heidelberg, Mannheim, Tübingen
2021-09-23
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Chemnitz, Frankfurt, Hanover, Kiel, Leipzig, Magdeburg, Münster, Tübingen
2021-09-22
Active, closed
Albireo, an Ipsen Company
Phase 3
62
Berlin, Hanover, Tübingen
2021-09-03
Active, closed
Vivet Therapeutics SAS
Phase 1/2
4
Essen, Tübingen
2021-09-03
Active, closed
Leipzig Heart Science gGmbH
Not applicable
836
Bad Berka, Bad Oeynhausen, Cologne, Dortmund, Giessen, Leipzig, München, Tübingen
2021-08-30
Active, closed
Hoffmann-La Roche
Phase 1
119
Dresden, Göttingen, München, Münster, Tübingen, Ulm
2021-08-11
Active, closed
Biotronik AG
Observational
160
Bayreuth, Essen, Flensburg, Jena, Münster, Tübingen
2021-08-10
By invitation
UCB Biopharma SRL
Phase 3
760
Cologne, Freiburg im Breisgau, Herne, Leipzig, Tübingen, Vogelsang-gommern
2021-07-27
Active, closed
University Hospital Tuebingen
Not applicable
30
Tübingen
2021-07-21
Active, closed
Bristol-Myers Squibb
Phase 3
729
Ratingen, Cologne, Erlangen, Hamburg, Magdeburg, Minden, Tübingen
2021-07-15
Active, closed
Ethicon, Inc.
Observational
198
Tübingen
2021-07-07
Recruiting
EyeConic: Qualification for Cone-Optogenetics
NCT05294978Retinal Dystrophies
Institute of Molecular and Clinical Ophthalmology Basel
Observational
1,000
Tübingen
2021-07-01
Recruiting
A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD
NCT04201210HbS Disease, Hemoglobin S Disease, Sickle Cell Anemia, Sickle Cell Disorders
University of Regensburg
Phase 2
212
Aachen, Berlin, Düsseldorf, Frankfurt, Heidelberg, Regensburg, Tübingen, Würzburg
2021-06-30
Active, closed
AstraZeneca
Phase 3
367
Berlin, Cologne, Leipzig, Tübingen
2021-06-08
Active, closed
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
NCT04765345Retinal Degeneration, Retinitis Pigmentosa, Eye Diseases, Hereditary
Jaeb Center for Health Research
Observational
44
Tübingen
2021-06-08
Recruiting
University Hospital Tuebingen
Not applicable
12,000
Tübingen
2021-06-01
Active, closed
Genentech, Inc.
Phase 1
65
Berlin, Hamburg, Mannheim, Tübingen, Würzburg
2021-05-13
Recruiting
Ipsen
Phase 1/2
240
Bonn, Düsseldorf, Goettigen, Hamburg, Mainz, Munich, Troisdorf, Tübingen
2021-04-29
Active, closed
Hoffmann-La Roche
Phase 3
557
Frankfurt, Hanover, Mainz, Tübingen, Ulm
2021-04-26
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
DrugPhase 2
enGene, Inc.
Phase 1/2
350
Cologne, Duisburg, Erlangen, Mettmann, Nürtingen, Tübingen
2021-04-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Freiburg im Breisgau, Tübingen, Regensburg, Würzburg, Herne, Münster, Dresden, Halle
2021-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Tübingen, Schwerin, Berlin
2021-04-14
Active, closed
Geron Corporation
Phase 3
327
Mannheim, Tübingen, Dresden, Leipzig, Halle
2021-04-12
Recruiting
Intermittent Fasting to Improve Insulin Secretion
NCT04607096PreDiabetes, Diabetes type2, Intermittent Fasting, Insulin Secretion
University Hospital Tuebingen
Not applicable
200
Berlin, Dresden, Düsseldorf, Heidelberg, Leipzig, Lübeck, Munich, Tübingen
2021-04-08
Recruiting
Study of BEST1 Vitelliform Macular Dystrophy
NCT05809635Best Vitelliform Macular Dystrophy, Retinitis Pigmentosa
Columbia University
Observational
52
Tübingen
2021-03-30
Recruiting
Guerbet
Phase 4
2,076
Tübingen, Berlin
2021-03-24
Active, closed
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
NCT04620239Transitional Cell Cancer of Renal Pelvis and Ureter
Steba Biotech S.A.
Phase 3
89
Tübingen
2021-03-22
Active, closed
Hoffmann-La Roche
Phase 3
746
Berlin, Böblingen, Dresden, Giessen, Kiel, Stuttgart, Tübingen, Ulm
2021-03-17
Active, closed
Promedon
Not applicable
180
Erfurt, Berlin, Freiburg im Breisgau, Leipzig, Tettnang, Tübingen
2021-03-10
Recruiting
University Hospital Tuebingen
Observational
12,000
Tübingen
2021-02-18
Active, closed
Go Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS®
NCT04113044Hip Fractures, Tibial Fractures, Ankle Fractures, Humeral Fracture, Proximal
AO Innovation Translation Center
Observational
1,500
Berlin, Freiburg im Breisgau, Homburg, Murnau am Staffelsee, Tübingen
2021-02-01
Recruiting
University Hospital Tuebingen
Observational
100
Tübingen
2021-01-15
Active, closed
Pfizer
Phase 3
257
Tübingen, München, Bonn, Minden, Mainz, Dresden, Leipzig, Kiel
2021-01-15
Active, closed
Edwards Lifesciences
Observational
300
Tübingen, Ulm, München, Cologne, Essen, Bad Oeynhausen, Bonn, Leipzig
2021-01-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Heilbronn, Ludwigsburg, Tübingen, Hanover, Bonn, Essen, Dresden, Lübeck
2021-01-10
Active, closed
Amgen
Phase 1/2
181
Augsburg, Berlin, Cologne, Jena, Leipzig, Tübingen, Ulm
2021-01-04
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
Hanover, Bonn, Berlin, Erlangen, Kiel, Leipzig, Magdeburg, Tübingen
2020-12-18
Active, closed
Hoffmann-La Roche
Phase 3
769
Dresden, Greifswald, Hanover, Leipzig, Münster, Tübingen, Ulm, Wiesbaden
2020-12-03
Active, closed
Prof. Dr. med. Claus Rödel
Phase 3
702
Esslingen am Neckar, Freiburg im Breisgau, Mannheim, Mutlangen, Offenburg, Ostfildern, Stuttgart, Tübingen
2020-11-05
Active, closed
Novartis Pharmaceuticals
Phase 2
134
Dresden, Essen, Heidelberg, Tübingen
2020-10-30
Active, closed
Hoffmann-La Roche
Phase 3
985
Berlin, Böblingen, Dresden, Freiburg im Breisgau, München, Tübingen, Wiesbaden
2020-10-26
Active, closed
Bayer
Phase 3
774
Emmendingen, Freiburg im Breisgau, Mühlacker, Nürtingen, Reutlingen, Tübingen, Erlangen, Braunschweig
2020-10-20
Active, closed
GlaxoSmithKline
Phase 3
302
Mainz, Tübingen, Würzburg
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 2
194
Heidelberg, Leipzig, Tübingen, Würzburg
2020-09-17
Active, closed
Women's Cancer Study Group GmbH
Phase 3
1,260
Freiburg im Breisgau, Heilbronn, Ravensburg, Ulm, Weinheim, Baden-Baden, Tübingen, Augsburg
2020-09-02
Active, closed
Hoffmann-La Roche
Phase 3
271
Berlin, Dresden, Freiburg im Breisgau, Mainz, Tübingen
2020-08-10
Recruiting
University Hospital Tuebingen
Observational
20
Tübingen
2020-08-01
Active, closed
Swiss Cancer Institute
Phase 2
90
Tübingen
2020-07-15
Recruiting
Safety and Early Signs of Efficacy of IL12-L19L19.
NCT04471987Advanced Solid Tumor, Metastatic Solid Tumor
Philogen S.p.A.
Phase 1
80
Hamburg, Heidelberg, Leipzig, Tübingen
2020-07-01
Recruiting
Michael J. Fox Foundation for Parkinson's Research
Observational
4,500
Hessen, Kassel, Lübeck, Tübingen
2020-07-01
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Cologne, Dresden, Hamburg, Leipzig, Tübingen, Würzburg
2020-06-12
Active, closed
GlaxoSmithKline
Phase 3
325
Berlin, Tübingen
2020-04-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Tübingen, Düsseldorf, Essen, Dresden, Magdeburg, Jena, Berlin, Hamburg
2020-02-27
Active, closed
Rate of Progression in EYS Related Retinal Degeneration
NCT04127006Retinitis Pigmentosa, Eye Diseases
Jaeb Center for Health Research
Observational
103
Tübingen
2020-02-25
Recruiting
University Hospital Tuebingen
Observational
600
Tübingen
2020-01-14
Recruiting
Department of Trauma and Reconstructive Surgery at Eberhard Karls University Tuebingen, BG Klinik Tu
Observational
850
Tübingen
2020-01-01
Active, closed
Pfizer
Phase 3
1,068
Duisburg, Frankfurt, Münster, Nürtingen, Tübingen
2019-12-30
Active, closed
GlaxoSmithKline
Phase 1
118
Dresden, Hamburg, Schwerin, Tübingen
2019-12-18
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Vascutek Ltd.
Observational
1,000
Augsburg, Berlin, Chemnitz, Freiburg im Breisgau, Göttingen, Lingen, Münster, Tübingen
2019-12-17
Recruiting
Genetic Causes of Discrepant Clinic in Monogenic Twins
NCT04046796Rare Diseases, Genetic Predisposition to Disease
University Hospital Tuebingen
Observational
50
Tübingen
2019-12-01
Active, closed
Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer
NCT04141709Oligometastatic Disease, Prostatic Cancer, Castration-Resistant
Technische Universität Dresden
Not applicable
66
Dresden, Freiburg im Breisgau, Heidelberg, Tübingen
2019-12-01
Recruiting
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
Abbott Medical Devices
Observational
1,000
Tübingen, Düsseldorf, Münster, Mainz, Homburg, Hamburg
2019-11-26
Active, closed
RhoVac APS
Phase 2
180
Dresden, Duisburg, Hagenow, Halle, Nürtingen, Tübingen
2019-11-19
Recruiting
University Hospital Tuebingen
Phase 1
86
Tübingen, Heidelberg
2019-11-15
Active, closed
Pazopanib Vs. Pazopanib Plus Gemcitabine
NCT02203760Leiomyosarcoma or Carcinosarcoma
DrugsPazopanib·Gemcitabine
North Eastern German Society of Gynaecological Oncology
Phase 2
58
Bonn, Berlin, Greifswald, Bad Saarow, Dresden, Essen, Jena, Tübingen
2019-10-16
Active, closed
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
DrugsVusolimogene Oderparepvec·Cemiplimab
Replimune, Inc.
Phase 2
231
Berlin, Essen, Hamburg, Heidelberg, München, Tübingen
2019-10-08
Active, closed
PDE6A Gene Therapy for Retinitis Pigmentosa
NCT04611503Retinitis Pigmentosa
STZ eyetrial
Phase 1/2
9
Tübingen
2019-09-24
Active, closed
TME Pharma AG
Phase 1/2
117
Bonn, Essen, Leipzig, Mannheim, Münster, Tübingen
2019-09-12
Active, closed
MiCLASP Post Market Clinical Follow-Up (PMCF) Study
NCT04430075Mitral Regurgitation, Mitral Insufficiency
Edwards Lifesciences
Observational
1,000
Bad Krozingen, Tübingen, Ulm, Erlangen, München, Bernau bei Berlin, Giessen, Göttingen
2019-08-23
Recruiting
Global Coalition for Adaptive Research
Phase 2/3
2,250
Cologne, Frankfurt, Heidelberg, Mannheim, Regensburg, Tübingen
2019-07-30
Active, closed
Swiss Cancer Institute
Phase 2
135
München, Berlin, Essen, Hamburg, Ludwigsburg, Tübingen, Ulm
2019-07-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Stuttgart, Tübingen, Erlangen, Munich, Würzburg, Bonn, Dresden, Magdeburg
2019-07-24
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
197
Berlin, Essen, Freiburg im Breisgau, Hamburg, Heilbronn, Leipzig, München, Tübingen
2019-07-17
Active, closed
IHF GmbH - Institut für Herzinfarktforschung
Not applicable
120
Tübingen, München, Hamburg, Bad Nauheim, Bad Bevensen, Rostock, Bad Oeynhausen, Cologne
2019-07-03
Active, closed
Women's Cancer Study Group GmbH
Phase 3
1,684
Aalen, Baden-Baden, Böblingen, Freiburg im Breisgau, Heilbronn, Ludwigsburg, Tübingen, Ulm
2019-07-02
Active, closed
Exelixis
Phase 3
855
Heidelberg, Tübingen, Frankfurt am Main, Münster, Mainz, Jena, Dresden
2019-06-25
Recruiting
Eli Lilly and Company
Phase 3
190
Berlin, Hamburg, Heidelberg, Sankt Augustin, Tübingen
2019-04-05
Active, closed
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
NCT03913143Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
DrugSepofarsen
ProQR Therapeutics
Phase 2/3
36
Giessen, Tübingen
2019-04-04
Recruiting
Abbott Medical Devices
Observational
2,000
Tübingen, Ingolstadt, Cologne, Duisburg, Düsseldorf, Mönchengladbach, Lübeck, Gera
2019-03-13
Recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT04075305Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer
UMC Utrecht
Observational
8,000
Tübingen
2019-02-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Tübingen, Ulm, Erlangen, Munich, München, Frankfurt am Main, Kassel, Cologne
2018-12-17
Recruiting
Technische Universität Dresden
Not applicable
304
Tübingen, Essen, Dresden, Berlin, Frankfurt am Main, Freiburg im Breisgau, Heidelberg, München
2018-11-29
Recruiting
GISAR German Interdisciplinary Sarcoma Registry
NCT04122872Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Carcinosarcoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Observational
9,000
Tübingen, Erlangen, Bad Saarow, Berlin, Berlin-Spandau, Frankfurt, Freiburg im Breisgau, Göttingen
2018-11-29
Active, closed
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
NCT03853616Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent
DrugMB-CART19.1
Miltenyi Biomedicine GmbH
Phase 1
48
Berlin, Erlangen, Göttingen, Munich, Münster, Tübingen, Würzburg
2018-11-26
Active, closed
Eli Lilly and Company
Phase 2/3
393
Nürtingen, Tübingen, Holzminden, Cologne, Mettmann, Münster, Wesel, Leipzig
2018-11-26
Active, closed
AbbVie
Phase 3
265
Stuttgart, Tübingen, Würzburg, Chemnitz, Kiel, Jena, Berlin, Hamburg
2018-10-22
Active, closed
Risk Factors in Tachycardiomyopathy
NCT03418467Atrial Fibrillation, Atrial Flutter, Ventricular Premature Complexes
University Hospital Tuebingen
Observational
60
Tübingen
2018-10-11
Active, closed
Exelixis
Phase 3
187
Tübingen, Würzburg, Marburg, Hanover, Dresden, Magdeburg, Aachen, Bonn
2018-10-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Mannheim, Tübingen, Munich, Nuremberg, Würzburg, Buxtehude, Hanover, Essen
2018-09-12
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Tübingen, Erlangen, Munich, Frankfurt am Main, Buxtehude, Hanover, Essen, Homburg
2018-08-21
Recruiting
The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4
NCT03206190Hereditary Spastic Paraplegia, Hereditary, Spastic Paraplegia, Autosomal Dominant
University Hospital Tuebingen
Not applicable
200
Tübingen
2018-07-01
Recruiting
University of Leipzig
Not applicable
120
Tübingen, München, Frankfurt am Main, Hanover, Witten, Mainz, Dresden, Leipzig
2018-06-18
Recruiting
Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac
NCT04172753Rectal Cancer, Head and Neck Cancer, Liver Cancer, Breast Cancer
University Hospital Tuebingen
Not applicable
472
Tübingen
2018-05-09
By invitation
International Registry of Congenital Portosystemic Shunt (IRCPSS)
NCT06041906Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
Prof. Valérie Mc Lin
Observational
500
Hanover, Munich, Tübingen
2018-04-26
Active, closed
Bristol-Myers Squibb
Phase 2/3
714
Heidelberg, Tübingen, Quedlinburg, Buxtehude, Cologne, Erfurt, Essen, Hanover
2018-04-11
Recruiting
Jena University Hospital
Not applicable
40
Jena, Tübingen
2018-04-10
Active, closed
Development of Novel Clinical Endpoints in Intermediate AMD
NCT03349801Age Related Macular Degeneration (AMD)
Frank G. Holz
Observational
718
Bonn, Cologne, Freiburg im Breisgau, Munich, Münster, Tübingen, Ulm
2018-03-26
Recruiting
University Hospital Tuebingen
Observational
1,000
Tübingen
2018-03-01
Recruiting
Tübinger Diabetes Mellitus Database (TUEDID)
NCT03658512Diabetes Mellitus
University Hospital Tuebingen
Observational
1,000
Tübingen
2018-02-05
Active, closed
Gilead Sciences
Phase 3
340
Berlin, Erlangen, Hamburg, Herne, Kiel, Tübingen
2017-12-12
Active, closed
Sanofi
Phase 3
475
Berlin, Frankfurt am Main, Heidelberg, Tübingen
2017-12-07
Active, closed
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
NCT02984410Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
Not applicable
112
Cologne, Halle, Hamburg, Jena, Leipzig, München, Tübingen, Ulm
2017-11-27
Recruiting
RWTH Aachen University
Phase 2
200
Tübingen, Regensburg, Essen, Berlin, Aachen, Bochum, Dortmund, Dresden
2017-11-20
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
DrugsCabozantinib·Tecentriq·Atezolizumab
Exelixis
Phase 1
914
Düsseldorf, Tübingen
2017-09-05
Active, closed
Rate of Progression in USH2A-related Retinal Degeneration
NCT03146078Usher Syndrome, Type 2A, Retinitis Pigmentosa 39
Jaeb Center for Health Research
Observational
127
Tübingen
2017-08-11
Active, closed
Eli Lilly and Company
Phase 3
5,637
Freiburg im Breisgau, Friedrichshafen, Ludwigsburg, Tübingen, Ulm, Amberg, Augsburg, Erlangen
2017-07-12
Active, closed
Hoffmann-La Roche
Phase 2
316
Berlin, Düsseldorf, Kassel, Leipzig, Marburg, München, Tübingen, Ulm
2017-06-27
Recruiting
MED-EL Elektromedizinische Geräte GmbH
Observational
100
Bochum, Dresden, Frankfurt, Heidelberg, München, Oldenburg, Rostock, Tübingen
2017-06-26
Active, closed
AbbVie
Phase 3
950
Mannheim, Tübingen, Frankfurt am Main, Munster, Herne, Saarbrücken, Kiel, Berlin
2017-01-31
Active, closed
Celgene
Phase 1/2
466
Dresden, Düsseldorf, Hamburg, Heidelberg, Tübingen, Würzburg
2016-10-14
Active, closed
Eisai Inc.
Phase 3
1,069
Stuttgart, Tübingen, München, Frankfurt am Main, Hanover, Greifswald, Münster, Homburg/Saar
2016-10-13
Active, closed
Philogen S.p.A.
Phase 3
214
Dresden, Hanover, Heidelberg, Kiel, Leipzig, Berlin, Tübingen, Augsburg
2016-07-01
Active, closed
AGO Study Group
Not applicable
797
Berlin, Dresden, Düsseldorf, Essen, Hamburg, München, Tübingen
2016-07
Active, closed
PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer
NCT03469674Endometrial Cancer Stage I, Endometrial Cancer Stage II
Leiden University Medical Center
Phase 3
550
Berlin, Düsseldorf, Essen, Heidelberg, Lübeck, Münich, Tübingen
2016-06-10
Active, closed
Eli Lilly and Company
Phase 2
309
Tübingen, Ulm, Erlangen, Hanover, Berlin, Hamburg
2016-05-19
Recruiting
Study of MR-based IGRT for Prostate Cancer
NCT02724670Prostate Cancer
University Hospital Tuebingen
Not applicable
78
Tübingen
2016-03
Active, closed
STZ eyetrial
Phase 1/2
13
Tübingen
2015-11
Active, closed
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
NCT02327845Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia
University of Miami
Observational
708
Tübingen
2015-04
Recruiting
Cerebellar Mutism Syndrome Study
NCT02300766Infratentorial Neoplasms, Mutism
Copenhagen University Hospital, Rigshospitalet
Observational
2,000
Leipzig, Tübingen
2014-10
Active, closed
Eli Lilly and Company
Phase 3
669
Ludwigsburg, Tübingen, Augsburg, München, Hamburg
2014-07-22
Recruiting
Praegnant Breast Cancer: Early/Advanced/Metastatic
NCT02338167Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
University Hospital Tuebingen
Observational
13,500
Böblingen, Freiburg im Breisgau, Heidelberg, Karlsruhe, Mannheim, Nürtingen, Tübingen, Ulm
2014-06
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Essen, Hanover, Heidelberg, Lübeck, Münster, Tübingen
2013-03-18
Active, closed
Washington University School of Medicine
Phase 2/3
490
Tübingen, Munich
2012-12
Recruiting
Gestational Diabetes
NCT04270578Gestational Diabetes
University Hospital Tuebingen
Observational
800
Tübingen
2012-05-23
Recruiting
University Hospital Tuebingen
Observational
580
Tübingen
2012-01
Recruiting
University of Hohenheim
Not applicable
480
Heidelberg, Stuttgart, Tübingen
2009-05
Recruiting
Dominantly Inherited Alzheimer Network (DIAN)
NCT00869817Alzheimer's Disease
Washington University School of Medicine
Observational
700
Munich, Tübingen
2009-01
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
751
Bamberg, Bonn, Hanover, Heidelberg, Regensburg, Tübingen
2007-12
Recruiting
The EUROSCA Natural History Study
NCT02440763Spinocerebellar Ataxia
Ataxia Study Group
Observational
400
Bochum, Bonn, Essen, Frankfurt, Tübingen
2005-07
Rows per page Showing 1–457 of 457
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-germany/city/t-bingen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,081 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 457 of those studies with a site in Tübingen.

How many clinical trials are recruiting in Tübingen?

248 of the 457 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 11 have not yet opened recruitment, 186 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tübingen), 457 studies
PhaseStudiesRecruitingShare
Phase 31324328.9%
Observational957120.8%
Phase 2764016.6%
Not applicable643814%
Phase 1/236237.9%
Phase 132197%
Phase 2/317103.7%
Phase 4430.9%
Early Phase 1110.2%

Most active sponsors

Lead sponsors with the most studies (Tübingen)
Lead sponsorStudiesRecruiting
University Hospital Tuebingen7863
Merck Sharp & Dohme LLC209
Hoffmann-La Roche122
AbbVie113
Novartis Pharmaceuticals115
Janssen Research & Development, LLC104
AstraZeneca93
Boehringer Ingelheim83
Eli Lilly and Company72
Pfizer74
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.